Cartesian Therapeutics (RNAC) Non-Current Assets (2015 - 2026)

Cartesian Therapeutics (RNAC) has 12 years of Non-Current Assets data on file, last reported at $166.4 million in Q1 2026.

• Non-Current Assets for Q1 2026 came in at $166.4 million, down 25.74% year-over-year; the trailing twelve-month figure through Mar 2026 was $784.4 million (down 12.02% YoY), and the FY2025 annual result was $167.1 million, down 23.47% from the prior year.
• Non-Current Assets steadied at $166.4 million in Q1 2026 per RNAC's latest filing, from $167.1 million in the prior quarter.
• Over five years, Non-Current Assets peaked at $226.2 million in Q3 2024 and troughed at $15.5 million in Q2 2022.
• A 5-year average of $130.7 million and a median of $167.1 million in 2025 frame the typical range for Non-Current Assets.
• The sharpest annual moves came in 2024 and 2026: Non-Current Assets surged 1299.2% in 2024, then decreased 25.74% in 2026.
• A 5-year view of Non-Current Assets shows it stood at $17.7 million in 2022, then surged by 1107.58% to $214.3 million in 2023, then rose by 1.9% to $218.4 million in 2024, then decreased by 23.47% to $167.1 million in 2025, then fell by 0.47% to $166.4 million in 2026.
• Business Quant data shows RNAC's Non-Current Assets at $166.4 million in Q1 2026, $167.1 million in Q4 2025, and $225.4 million in Q3 2025.